Want to see IN:CONCORDBIO full AI Analyst Report?
Top Page
Concord Biotech Ltd.
(CONCORDBIO)
Select Model
Select Model
Rating:76Outperform
Price Target:
₹1,599.00
▲(28.06% Upside)
Action:Upgraded
Date:08/19/26
Score is driven primarily by strong financial resilience (excellent balance sheet and solid profitability) and bullish technical trend signals. This is meaningfully offset by expensive valuation (high P/E and low yield) and some recent softening in operating momentum (2026 revenue decline and margin compression).
Positive Factors
Conservative Balance Sheet
Minimal debt and a very low debt-to-equity profile reduce financial risk and preserve flexibility. The steadily growing equity base and consistently positive returns on equity provide a durable foundation for funding operations, absorbing volatility, and supporting future investment.
Negative Factors
Revenue Contraction
The 2026 annual revenue decline interrupts the company’s earlier expansion pattern and signals weaker recent demand or business momentum. If contraction persists, it could reduce operating leverage, limit reinvestment capacity, and make sustained earnings growth harder to achieve.
Read all positive and negative factors
Positive Factors
Negative Factors
Conservative Balance Sheet
Minimal debt and a very low debt-to-equity profile reduce financial risk and preserve flexibility. The steadily growing equity base and consistently positive returns on equity provide a durable foundation for funding operations, absorbing volatility, and supporting future investment.
Read all positive factors
Concord Biotech Ltd. (CONCORDBIO) vs. iShares MSCI India ETF (INDA)
Market Cap
₹150.91B
Dividend Yield0.51%
Average Volume (3M)88.52K
Price to Earnings (P/E)56.0
Beta (1Y)1.18
Revenue Growth-6.72%
EPS Growth-22.67%
CountryIN
Employees1,624
SectorGeneral
Sector StrengthN/A
IndustryBiotechnology
Share Statistics
EPS (TTM)26.24
Shares Outstanding104,616,200
10 Day Avg. Volume224,934
30 Day Avg. Volume88,520
Financial Highlights & Ratios
PEG Ratio-1.36
Price to Book (P/B)5.32
Price to Sales (P/S)10.16
P/FCF Ratio61.58
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)32.65
Revenue Forecast (FY)₹12.94B
Concord Biotech Ltd. Business Overview & Revenue Model
Company Description
Concord Biotech Limited, a biopharma company, engages in the research and development, manufacture, market, and sale of pharmaceutical products in India and internationally. The company provides fermentation based active pharmaceutical ingredients...
How the Company Makes Money
Concord Biotech primarily makes money by manufacturing and selling fermentation-based APIs to pharmaceutical companies. Its main revenue stream is API sales, where it produces complex molecules (notably in areas like immunosuppressants and oncolog...
Concord Biotech Ltd. Financial Statement Overview
Summary
Income Statement
78
Positive
Balance Sheet
94
Very Positive
Cash Flow
73
Positive
| Breakdown | TTM | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 11.08B | 10.55B | 12.00B | 10.17B | 8.53B | 7.13B |
| Gross Profit | 5.66B | 4.42B | 7.68B | 6.67B | 6.61B | 5.41B |
| EBITDA | 4.25B | 4.19B | 5.13B | 4.39B | 3.53B | 2.78B |
| Net Income | 2.75B | 2.61B | 3.72B | 3.08B | 2.40B | 1.75B |
Balance Sheet | ||||||
| Total Assets | 0.00 | 22.35B | 20.34B | 17.01B | 15.14B | 13.13B |
| Cash, Cash Equivalents and Short-Term Investments | 4.32B | 4.16B | 3.18B | 2.86B | 1.81B | 1.62B |
| Total Debt | 0.00 | 23.16M | 29.69M | 97.38M | 315.47M | 624.93M |
| Total Liabilities | -20.15B | 2.20B | 2.22B | 1.74B | 2.24B | 2.10B |
| Stockholders Equity | 20.15B | 20.17B | 18.13B | 15.27B | 12.90B | 11.03B |
Cash Flow | ||||||
| Free Cash Flow | 975.85M | 1.74B | 1.36B | 1.80B | 1.01B | 519.70M |
| Operating Cash Flow | 1.51B | 2.69B | 2.47B | 2.65B | 2.46B | 2.07B |
| Investing Cash Flow | -212.84M | -1.45B | -1.63B | -1.55B | -1.58B | -1.12B |
| Financing Cash Flow | -1.13B | -1.13B | -986.67M | -992.15M | -852.19M | -1.00B |
Concord Biotech Ltd. Technical Analysis
Positive
1248.65
Price Trends
1392.39
Positive
1286.66
Positive
1261.89
Positive
Market Momentum
13.62
Positive
52.87
Neutral
24.91
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:CONCORDBIO, the sentiment is Positive. The current price of 1248.65 is below the 20-day moving average (MA) of 1495.16, below the 50-day MA of 1392.39, and below the 200-day MA of 1261.89, indicating a neutral trend. The MACD of 13.62 indicates Positive momentum. The RSI at 52.87 is Neutral, neither overbought nor oversold. The STOCH value of 24.91 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for IN:CONCORDBIO.
Concord Biotech Ltd. Peers Comparison
UnderperformOutperform
Sector (55)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
77 Outperform | ₹526.25B | 93.44 | ― | 0.21% | ― | ― | |
76 Outperform | ₹150.91B | 56.04 | ― | 0.51% | -6.72% | -22.67% | |
58 Neutral | ₹23.21B | -337.80 | ― | 0.56% | 10.26% | -162.02% | |
56 Neutral | ₹26.87B | 40.00 | ― | 0.11% | -20.86% | -34.51% | |
55 Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% | |
55 Neutral | ₹157.21B | 70.46 | ― | 0.32% | -3.41% | -56.45% | |
49 Neutral | ₹640.66B | 115.38 | ― | 0.13% | 9.83% | 5.07% |
* General Sector Average
IN:CONCORDBIO
Concord Biotech Ltd.
1,469.70
-190.86
-11.49%
IN:BIOCON
Biocon Limited
392.55
29.04
7.99%
IN:DCAL
Dishman Carbogen Amcis Ltd.
173.85
-97.80
-36.00%
IN:PANACEABIO
Panacea Biotec Limited
393.40
-33.25
-7.79%
IN:SYNGENE
Syngene International Ltd.
387.50
-263.56
-40.48%
IN:ANTHEM
Anthem Biosciences Limited
957.80
144.42
17.76%
Concord Biotech Ltd. Corporate Events
Concord Biotech Clears Kenya and Uganda Inspections at Unit-II Plant
Jun 25, 2026
Concord Biotech has announced that regulators from Kenya and Uganda have successfully completed inspections of its Unit-II formulation facility in Gujarat. The Pharmacy and Poisons Board of Kenya and Uganda’s National Drug Authority conducte...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.